Effects of Resveratrol Supplementation on Methotrexate Chemotherapy-Induced Bone Loss

@article{Lee2017EffectsOR,
  title={Effects of Resveratrol Supplementation on Methotrexate Chemotherapy-Induced Bone Loss},
  author={Alice M. C. Lee and Tetyana Shandala and Pei Pei Soo and Yu‐wen Su and Tristan J. King and Ke-Ming Chen and Peter R. C. Howe and Cory J. Xian},
  journal={Nutrients},
  year={2017},
  volume={9}
}
Intensive cancer chemotherapy is known to cause bone defects, which currently lack treatments. This study investigated the effects of polyphenol resveratrol (RES) in preventing bone defects in rats caused by methotrexate (MTX), a commonly used antimetabolite in childhood oncology. Young rats received five daily MTX injections at 0.75 mg/kg/day. RES was orally gavaged daily for seven days prior to, and during, five-day MTX administration. MTX reduced growth plate thickness, primary spongiosa… Expand
Childhood cancer chemotherapy–induced bone damage: pathobiology and protective effects of resveratrol and other nutraceuticals
TLDR
Preclinical studies that, in some cases, indicate efficacy in reducing chemotherapy‐induced bone defects are described, including resveratrol, genistein, icariin, and inflammatory fatty acids. Expand
Short-term use of resveratrol in alloplastic graft material applied with calvarial bone defects in rats 1
TLDR
Resveratrol treatment was thought to be an alternative and supportive drug for implant application by inducing new bone formation in the calvaral defect region as a result of short-term treatment. Expand
Effect of Methotrexate Injection on Orthodontic Tooth Movement: An Experimental Study on Rats
Introduction Knowledge about the effects of medications, vitamins, and various supplements on orthodontic tooth movement (OTM) is imperative for orthodontists. This study aimed to assess the effectExpand
Regular Supplementation With Resveratrol Improves Bone Mineral Density in Postmenopausal Women: A Randomized, Placebo‐Controlled Trial
TLDR
Regular supplementation with 75 mg of resveratrol twice daily has the potential to slow bone loss in the lumbar spine and femoral neck, common fracture sites in postmenopausal women without overt osteoporosis. Expand
Resveratrol as an adjuvant for normal tissues protection and tumor sensitization.
TLDR
The potential role of resveratrol for preserving normal tissues and sensitization of cancer cells in combination with different cancer treatment modalities is reviewed. Expand
Inhibitory effects of resveratrol on orthodontic tooth movement and associated root resorption in rats.
TLDR
RSV could reduce the extent of OTM and root resorption areas and was more obvious than that of 5 mg/kg/d RSV group (p<0.05). Expand
Dietary nutraceuticals as backbone for bone health.
TLDR
The nutraceuticals identified from dietary agents such as butein, cardamonin, coronarin D curcumin, diosgenin, embelin, gambogic acid, genistein, plumbagin, quercetin, reseveratrol, zerumbone and more, can modulate cell signaling pathways and reverse/slow down osteoporosis. Expand
Nutraceutical Boom in Cancer: Inside the Labyrinth of Reactive Oxygen Species
TLDR
This review highlighted the emerging opinions and data on the pros and cons on the use of nutraceutical supplements during chemotherapy, and suggested that high levels of them may interfere with the effectiveness of chemotherapy, making cancer cells less reactive to chemotherapy. Expand
Nano‐delivery systems for encapsulation of dietary polyphenols: An experimental approach for neurodegenerative diseases and brain tumors
TLDR
An overview of the primary polyphenols used for ND and brain tumor prevention and treatment is provided by focusing on recent findings, the principal factors limiting their application in clinical practice, and a promising delivery strategy to improve their bioavailability. Expand
Integrated Cancer Treatment in the Course of Metastatic Pancreatic Cancer: Complete Resolution in 2 Cases
TLDR
In both cases, an integrated cancer treatment approach, combining chemotherapy with natural remedies, extracts, and hyperthermia, induced a notable remission of primary and metastatic lesions. Expand
...
1
2
...

References

SHOWING 1-10 OF 53 REFERENCES
Methotrexate chemotherapy reduces osteogenesis but increases adipogenic potential in the bone marrow
TLDR
Findings indicate that MTX chemotherapy reduces the bone marrow stromal progenitor cell population and induces a switch in differentiation potential towards adipogenesis at the expense of osteogenesis, resulting in osteopenia and marrow adiposity. Expand
Cellular mechanisms for methotrexate chemotherapy-induced bone growth defects.
TLDR
Observations suggest that methotrexate chemotherapy may cause bone growth defects by arresting cellular activities in the growth plate in producing calcified cartilage and primary trabecular bone and by decreasing pools of metaphyseal osteoblastic cells. Expand
Folinic acid attenuates methotrexate chemotherapy‐induced damages on bone growth mechanisms and pools of bone marrow stromal cells
TLDR
It is suggested that FA supplementation effectively attenuates MTX damage on cellular activities in producing calcified cartilage and primary trabecular bone and on pools of osteoblastic cells and marrow stromal cells, and that it enhances proliferation of mesenchymal progenitor cells during bone/bone marrow recovery. Expand
Prevention of Bone Growth Defects, Increased Bone Resorption and Marrow Adiposity with Folinic Acid in Rats Receiving Long-Term Methotrexate
TLDR
F folinic acid supplementation during chronic methotrexate treatment can alleviate growth plate and metaphyseal damages and therefore may be potentially useful in paediatric patients who are at risk of skeletal growth suppression due to chronic metotrexate chemotherapy. Expand
Damaging effects of chronic low-dose methotrexate usage on primary bone formation in young rats and potential protective effects of folinic acid supplementary treatment.
TLDR
It is suggested that acute use of MTX can damage growth plate and primary bone at a high dose, but not at a low dose, and supplementary treatment with folinic acid may be potentially useful in protecting bone growth during long-term low-dose MTX chemotherapy. Expand
Methotrexate‐Induced Bone Marrow Adiposity Is Mitigated by Folinic Acid Supplementation Through the Regulation of Wnt/β‐Catenin Signalling
TLDR
Evidence is provided that folate depletion caused by MTX chemotherapy results in increased bone marrow adiposity, and that FA rescue alleviates these defects by up‐regulating Wnt/β‐catenin signalling in the bone. Expand
Attenuated Wnt/β-catenin signalling mediates methotrexate chemotherapy-induced bone loss and marrow adiposity in rats.
TLDR
Findings demonstrate a potentially important role of Wnt/β-catenin signalling in MTX chemotherapy-induced cellular changes to the bone marrow microenvironment and partially abrogated the MTX-induced transient changes in osteogenic/adipogenic commitment, granulocyte/macrophage lineage differentiation and osteoclast number. Expand
The role of osteocyte apoptosis in cancer chemotherapy‐induced bone loss
TLDR
In vivo and in vitro data suggested that MTX‐induced apoptosis of osteocytes caused higher recruitment of DMP‐1 positive osteocytes and increased osteoclast formation, which could contribute towards the loss of bone homeostasis in vivo. Expand
Methotrexate chemotherapy promotes osteoclast formation in the long bone of rats via increased pro-inflammatory cytokines and enhanced NF-κB activation.
TLDR
It is shown that MTX induces osteoclast differentiation by generating a pro-osteoclastogenic environment in both bone and the circulation, specifically with increased TNF-α levels and activation of NF-κB. Expand
Combination chemotherapy with cyclophosphamide, epirubicin and 5-fluorouracil causes trabecular bone loss, bone marrow cell depletion and marrow adiposity in female rats
TLDR
Overall, this study indicates that six cycles of CEF chemotherapy may induce some bone loss and severe bone marrow damage. Expand
...
1
2
3
4
5
...